WHO ARV guidelines, Operational Guideline Development Group, day 2, session 9, 17 June 2015 **▶**DECIDE Evidence to decision-making framework

F1.1 and F1.2 Strengthening the cascade: frequency of clinic visits and pick ups

GRADE summary of evidence for pairwise comparisons of frequency of clinic visits

			Quality ass	essment					Summary	of Findings	
Participants (studies) Follow up	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	Overall quality of evidence	Study event rates (%)		Relative	Anticipated absolute effects	
							With Standard of care	With Less frequent clinic visits	effect (95% CI)	Risk with Standard of care	Risk difference with Less frequent clinic visits (95% CI)
Mortality	(CRITICAL	OUTCOME; asses	sed with: All cause	mortality)			0			Ti.	
4985 (5 studies) 24 months	serious ¹	serious ²	no serious indirectness	no serious imprecision	undetected	⊕⊝⊝ VERY LOW ^{1,2} due to risk of bias, inconsistency	143/3287 (4.4%)	154/1698 (9.1%)	OR 1.12 (0.60 to 2.10)	44 per 1000	5 more per 1000 (from 17 fewer to 44 more)
Morbidity	(CRITICAL	OUTCOME; asses	ssed with: Opportur	nistic infections or \	NHO stage III/IV)						
1100 (3 studies) 12.8 months	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	undetected	⊕⊜⊜⊝ VERY LOW ¹ due to risk of bias	45/394 (11.4%)	49/706 (6.9%)	OR 0.61 (0.35 to 1.05)	114 per 1000	41 fewer per 1000 (from 71 fewer to 5 more)
Retentio	n (CRITICA	L OUTCOME; asse	ssed with: Loss to	follow-up)							
15989 (5 studies) 12 months	serious ³	serious ⁴	no serious indirectness	no serious imprecision	undetected	⊕⊝⊝⊝ VERY LOW ^{3,4} due to risk of bias, inconsistency	4581/5836 (78.5%)	9501/10153 (93.6%)	OR 1.90 (1.21 to 2.99)	785 per 1000	89 more per 1000 (from 30 more to 131 more)
Adheren	Ce (CRITIC	AL OUTCOME; as:	sessed with: Dichot	omous measures)							
2442 (3 studies) 12.8 months	serious ^{1,5}	serious	no serious indirectness	no serious imprecision	undetected	⊕⊖⊖⊝ VERY LOW ^{1,5} due to risk of bias, inconsistency	844/926 (91.1%)	1450/1516 (95.6%)	OR 2.00 (0.53 to 7.60)	911 per 1000	42 more per 1000 (from 66 fewer to 76 more)
Viral failu	ure (CRITIC	CAL OUTCOME; as	ssessed with: Detec	table viremia or vira	al rebounds)						
7048 (6 studies) 24 months	serious ¹	serious ²	no serious indirectness	no serious imprecision	undetected	⊕⊝⊝⊝ VERY LOW ^{1,2} due to risk of bias, inconsistency	821/5241 (15.7%)	193/1807 (10.7%)	OR 0.83 (0.51 to 1.36)	157 per 1000	23 fewer per 1000 (from 70 fewer to 45 more)

¹ Inclusion of observational studies with selective inclusion to the intervention is likely to bias results

Evidence to decision-making framework

² High heterogeneity due to differences in settings and time periods within the ART scale-up

³ Only one study adjusted for covariates and adjustment is somewhat crude

⁴ I-squared is > 80%

⁵ Definitions of outcome differ



WHO ARV guidelines, Operational Guideline Development Group, day 2, session 9, 17 June 2015 **▶**DECIDE Evidence to decision-making framework

F1.1 and F1.2 Strengthening the cascade: frequency of clinic visits and pick ups

GRADE summary of evidence for pairwise comparisons of frequency of clinic drug pick-ups

Quality assessment								S	ummary o	f Findings	
	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	Overall quality of evidence	Study event rates (%)		Relative	Anticipated absolute effects	
(studies) Follow up							With Control	With Less frequent drug refills	effect (95% CI)	Risk with Control	Risk difference with Less frequent drug refills (95% CI)
Mortality	(CRITICAL OU	TCOME; assessed	d with: All cause m	ortality)		#				*	
1860 (1 study) 4 months	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	undetected	⊕⊝⊝⊝ VERY LOW ¹ due to imprecision	0/806 (0%)	0/1054 (0%)	LFS.	See comment	-
Retentio	n (CRITICAL O	UTCOME; assess	ed with: Loss to fol	low-up)	-		W				
12388 (2 studies) 15 months	serious ²	serious ³	no serious indirectness	no serious imprecision	undetected	⊕⊖⊖⊖ VERY LOW ^{2,3} due to risk of bias, inconsistency	2433/2806 (86.7%)	9053/9582 (94.5%)	OR 1.93 (0.62 to 6.04)	867 per 1000	59 more per 1000 (from 65 fewer to 108 more)
Adheren	Ce (CRITICAL	OUTCOME; asses	ssed with: Dichotor	nous measures)			V.				
2442 (1 study) 12.8 months	serious ⁴	no serious inconsistency	no serious indirectness	serious ⁵	reporting bias strongly suspected ⁶	●⊖⊝⊖ VERY LOW ^{4,5,6} due to risk of bias, imprecision, publication bias	844/926 (91.1%)	1450/1516 (95.6%)	OR 2.00 (0.53 to 7.6)	911 per 1000	42 more per 1000 (from 66 fewer to 76 more)
Viral failu	ure (assessed	with: Detectable v	riremia or viral rebo	unds)					1		
1860 (1 study) 4 months	serious	no serious inconsistency	no serious indirectness	serious	undetected	⊕⊖⊝⊖ VERY LOW due to risk of bias, imprecision	23/806 (2.9%)	31/1054 (2.9%)	OR 1.03 (0.6 to 1.78)	29 per 1000	1 more per 1000 (from 11 fewer to 21 more)

¹ Zero events reported

Evidence to decision-making framework 2

² Short follow-up time; 4 month period allowing for the evaluation of a single pick-up cycle

³ Very high I-squared

⁴ Data provided in a poster abstract; Very few details provided to assess risk of bias

⁵ Very few non-events

⁶ Poster abstract from 2004; Never published into a paper